نتایج جستجو برای: androgen antagonist
تعداد نتایج: 82143 فیلتر نتایج به سال:
Although risk assessments are typically conducted on a chemical-by-chemical basis, the 1996 Food Quality Protection Act (FQPA) required the Environmental Protection Agency (EPA) to consider cumulative risk of chemicals that act via a common mechanism of toxicity. To this end, we are conducting studies with mixtures to provide a framework for assessing the cumulative effects of “antiandrogenic” ...
OBJECTIVES To evaluate efficacy and safety of gonadotropin-releasing hormone (GnRH) antagonists compared to standard androgen suppression therapy for advanced prostate cancer. SETTING The international review team included methodologists of the German Cochrane Centre and clinical experts. PARTICIPANTS We searched CENTRAL, MEDLINE, Web of Science, EMBASE, trial registries and conference book...
Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance are androgen receptor (AR) overexpression, androgen-independent activation of AR, and AR mutation. To address this problem, we developed an AR pure antagonist, CH5137291, with AR nuclear translocation-inhibiting activity, and compared its activity and characteristics ...
INTRODUCTION Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians and patients have a choice between orchiectomy, luteinizing hormone releasing hormone (LHRH) agonists, combined androgen deprivation (CAD) or LHRH antagonists. MATERIALS AND METHODS Literature relating to the use of LHRH antagonists in the management of prostate ca...
Four experiments were performed with male and female rats of the inbred strain LEW/Ztm maintained under a light-dark schedule of 12:12 hours. The animals were subject to castration (GOX) or ovariectomy (OVX), estradiol 17 beta-implantation (E2-capsules), and perinatal hormonal treatments with testosterone propionate (TP) and an androgen antagonist (cyproterone acetate, CA). Results indicated a ...
Prostate cancer is an androgen-dependent disease, and androgen blockade is the primary treatment for metastatic prostate cancer. However, the tumors become resistant within a relatively short time. The recurrent tumors, surprisingly, typically overexpress androgen receptor and a subset of androgen-regulated genes including prostate-specific antigen (PSA). The mechanism for this reactivation is ...
The antiandrogenic drug, flutamide, is widely used in the treatment of carcinoma of the prostate. The present study examines the metabolism of flutamide by human liver microsomes and purified recombinant human cytochrome P450s (CYP), expressed as fusion proteins. These studies show the principal role of CYP1A2 in the metabolism of flutamide to 2-hydroxyflutamide. A minor metabolite is formed du...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید